Showing results (2761-2770 of 3,717) with videos related to
Sort By:
Pageof 372
Investigational New Drugs|July 7, 2023
Indirect comparisons of efficacy of zanubrutinib versus orelabrutinib in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma or relapsed or refractory mantle cell lymphomaYuqin Song, Keshu Zhou, Shenmiao Yang, et al.Investigational New Drugs|July 4, 2023
The p53 reactivator PRIMA-1MET synergises with 5-fluorouracil to induce apoptosis in pancreatic cancer cellsIbtehal Mohammed, Ali Haider Alhammer, Inam Sameh ArifInvestigational New Drugs|June 22, 2026
Evaluating pegenzileukin (SAR444245/THOR-707) in combination with pembrolizumab or cetuximab in advanced metastatic gastrointestinal cancer: the PEGATHOR phase 2 studyWilliam P Harris, Pilar García-Alfonso, Jean Phillipe Metges, et al.Investigational New Drugs|January 1, 1996
Clinical phase I and pharmacokinetic trial of the new titanium complex budotitaneT Schilling, K B Keppler, M E Heim, et al.Investigational New Drugs|March 27, 2026
Clinical pharmacokinetic characteristics and the food effect of radotinibYerin Lee, Jiwon Kim, Minseo Kang, et al.Investigational New Drugs|April 9, 2026
Recent progress of dendritic cell-derived exosomes in tumor immunotherapyBaiyan Wang, Yirui Hu, Yujia Zhou, et al.Investigational New Drugs|August 26, 2026
Inhibition of SHP2 enhances the effects of selective receptor tyrosine kinase inhibitors in untreated preclinical models of RET-mutated thyroid cancerWenjun Xie, Mengrang Tian, Weike Ma, et al.Investigational New Drugs|August 2, 2003
Noninvasive methods to study drug distributionRuediger E Port, Walter WolfInvestigational New Drugs|August 2, 2003
Mechanistic models for myelosuppressionLena E Friberg, Mats O KarlssonInvestigational New Drugs|June 11, 2003
An overview on the antileukemic potential of D-homo-aza- and respective 17beta-acetamido-steroidal alkylating estersCharalambos Camoutsis, Dimitrios T P TrafalisPageof 372